ACHL vs. SABS, PLUR, ESLA, INKT, BCLI, QNCX, SRZN, CYTH, OKYO, and DYAI Should you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include SAB Biotherapeutics (SABS), Pluri (PLUR), Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), Brainstorm Cell Therapeutics (BCLI), Quince Therapeutics (QNCX), Surrozen (SRZN), Cyclo Therapeutics (CYTH), OKYO Pharma (OKYO), and Dyadic International (DYAI). These companies are all part of the "biological products, except diagnostic" industry.
Achilles Therapeutics (NASDAQ:ACHL ) and SAB Biotherapeutics (NASDAQ:SABS ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.
Achilles Therapeutics and SAB Biotherapeutics both received 17 outperform votes by MarketBeat users. However, 73.91% of users gave SAB Biotherapeutics an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
In the previous week, Achilles Therapeutics had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for Achilles Therapeutics and 0 mentions for SAB Biotherapeutics. Achilles Therapeutics' average media sentiment score of 0.49 beat SAB Biotherapeutics' score of 0.00 indicating that Achilles Therapeutics is being referred to more favorably in the media.
Achilles Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 322.03%. SAB Biotherapeutics has a consensus price target of $15.50, indicating a potential upside of 327.00%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than Achilles Therapeutics.
Achilles Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
SAB Biotherapeutics has higher revenue and earnings than Achilles Therapeutics.
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 26.0% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Achilles Therapeutics has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -1,884.10%. Achilles Therapeutics' return on equity of -42.95% beat SAB Biotherapeutics' return on equity.
Summary Achilles Therapeutics and SAB Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ACHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Achilles Therapeutics Competitors List
Related Companies and Tools
